Full Press Release Details
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis.
ARGX
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Key Takeaway: argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis